Comparison of recombinant transforming growth factor-beta-2 and placebo as an adjunctive agent for macular hole surgery

Ophthalmology

Volumn 105, Issue 4, 1998, Pages 700-706

  Thompson, John T ^a,e   Smiddy, William E ^b   Williams, George A ^c   Sjaarda, Raymond N ^a   Flynn Jr , Harry W ^b   Margherio, Raymond R ^c   Abrams, Gary W ^d  

^a Retina Specialists   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c ASSOCIATED RETINAL CONSULTANTS   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA2;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IDIOPATHIC DISEASE; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETINA MACULA HOLE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 0031942736     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(98)94027-1     Document Type: Article

References (22)

1. Funata M, Wendel RT, de la Cruz Z, Green WR. Clinicopathologic study of bilateral macular holes treated with pars plana vitrectomy and gas tamponade. Retina 1992; 12:289-98.
2. Madreperla SA, Geiger GL, Funata M, et al. Clinicopathologic correlation of a macular hole treated by cortical vitreous peeling and gas tamponade. Ophthalmology 1994; 101:682-6.
3. Sjaarda RN, Frank DA, Glaser BM, et al. Resolution of an absolute scotoma and improvement of relative scotomata after successful macular hole surgery. Am J Ophthalmol 1993;116:129-39.
4. Kelly NE, Wendel RT. Vitreous surgery for idiopathic macular holes. Results of a pilot study. Arch Ophthalmol 1991;109:654-9.
5. Wendel RT, Patel AC, Kelly NE, et al. Vitreous surgery for macular holes. Ophthalmology 1993;100:1671-6.
6. Ruby AJ, Williams DF, Grand MG, et al. Pars plana vitrectomy for treatment of stage 2 macular holes. Arch Ophthalmol 1994;112:359-64.
7. Orellana J, Lieberman RM. Stage III macular hole surgery. Br J Ophthalmol 1993;77:555-8.
8. Ryan EH Jr, Gilbert HD. Results of surgical treatment of recent-onset full-thickness idiopathic macular holes. Arch Ophthalmol 1994;112:1545-53.
9. Glaser BM, Michels RG, Kuppermann BD, et al. Transforming growth factor-beta 2 for the treatment of full-thickness macular holes. A prospective randomized study. Ophthalmology 1992;99:1162-72.
10. Lansing MB, Glaser BM, Liss H, et al. The effect of pars plana vitrectomy and transforming growth factor-beta 2 without epiretinal membrane peeling on full-thickness macular holes. Ophthalmology 1993;100:868-71.
11. Smiddy WE, Glaser BM, Thompson JT, et al. Transforming growth factor β-2 significantly enhances the ability to flatten the rim of subretinal fluid surrounding macular holes: preliminary anatomic results of a multicenter prospective randomized study. Retina 1993;13:296-301.
12. Thompson JT, Glaser BM, Sjaarda RN, et al. Effects of intraocular bubble duration in the treatment of macular holes by vitrectomy and transforming growth factor-beta 2. Ophthalmology 1994;101:1195-200.
13. Ie D, Glaser BM, Thompson JT, et al. Retreatment of full-thickness macular hole persisting after prior vitrectomy: a pilot study. Ophthalmology 1993;100:1787-93.
14. Liggett PE, Skolik DSA, Horio B, et al. Human autologous serum for the treatment of full-thickness macular holes: a preliminary study. Ophthalmology 1995;102:1071-6.
15. Gaudric A, Massin P, Paques M, et al. Autologous platelet concentrate for the treatment of full-thickness macular holes. Graefes Arch Clin Exp Ophthalmol 1995;233:549-54.
16. Early Treatment Diabetic Retinopathy Study (ETDRS). Manual of Operations. 1986. Available from the National Technical Information Service (Accession #PBB5223006).
17. Thompson JT, Glaser BM, Sjaarda RN, Murphy RP. Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes. Am J Ophthalmol 1995;119:48-54.
18. Gass JD. Idiopathic senile macular hole. Its early stages and pathogenesis. Arch Ophthalmol 1988;106:629-39.
19. Johnson RN, Gass JD. Idiopathic macular holes. Observations, stages of formation, and implications for surgical intervention. Ophthalmology 1988;95:917-24.
20. Gass JD. Reappraisal of biomicroscopic classification of stages of development of a macular hole. Am J Ophthalmol 1995;119:752-9.
21. Thompson JT, Hiner CJ, Glaser BM, et al. Fluorescein angiographic characteristics of macular holes before and after vitrectomy with transforming growth factor beta-2. Am J Ophthalmol 1994;117:291-301.
22. Rubin JS, Thompson JT, Sjaarda RN, et al. Efficacy of fluid-air exchange during pars plana vitrectomy. Retina 1995;15:291-4.